OR WAIT null SECS
PharmaVigilant, a clinical trial technology provider, has been selected by Supernus Pharmaceuticals to support two studies focused on the development of new drugs to treat central nervous system diseases. Supernus will implement PharmaVigilant's InSpire EDC solution, I-Vault, I-Warehouse and Remote Source Document Verification (rSDV) to support the preparation, conduct and closeout of two trials that are currently in progress.
According to Paolo Baroldi, M.D., Ph.D., Chief Medical Officer at Supernus Pharmaceuticals. Inc., "We were attracted to PharmaVigilant because it offers a cost effective solution that will benefit us in terms of speed, integration and efficiency. PharmaVigilant's integration with CROs will also allow us greater flexibility and accessibility to our data, making the entire process easier to manage at every level."
PharmaVigilant's technology offers sponsors flexibility and transparency of their data. With this technology, Supernus gains control of all data and documents including source documents across continents and across clinical services providers. PharmaVigilant offers a full suite of clinical trial technology offerings including Electronic Data Capture (EDC), data warehousing, study building (I-Builder 2.0), Electronic Trial Master File System (eTMF), Remote Source Document Verification (rSDV), study administration and an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies.